NRX Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $1.2M | $0 | $0 |
| Cost of Revenue | $505.0K | $0 | — |
| Gross Profit | $720.0K | $0 | — |
| Gross Margin | 58.8% | — | — |
| Operating Expenses | |||
| Research & Development | $3.8M | $6.2M | $13.4M |
| SG&A Expense | $13.1M | $13.5M | $14.2M |
| Operating Income | $-16.2M | $-18.5M | $-27.8M |
| Operating Margin | -1,324.4% | — | — |
| Interest Expense | — | — | $120.0K |
| Pretax Income | — | — | — |
| Income Tax Expense | $0 | $0 | $0 |
| Net Income | $-28.6M | $-25.1M | $-30.2M |
| Net Margin | -2,336.5% | — | — |
| EPS (Basic) | $-1.34 | $-1.18 | $-1.99 |
| EPS (Diluted) | — | — | — |
| Shares Outstanding (Basic) | 21.4M | 21.3M | 15.2M |
| Shares Outstanding (Diluted) | 21.4M | 21.3M | 15.2M |
| Dividends Per Share | — | — | — |